Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
Status:
Active, not recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This trial studies how well the drug tucatinib works when given with trastuzumab and when
given by itself. The participants in this trial have HER2-positive (HER2+) metastatic
colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the
body.
In the first part of this study, participants enrolled into Cohort A and received both
tucatinib and trastuzumab. In the second part of this study, participants are randomly
assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and
trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do
not respond to therapy may have an option to receive tucatinib plus trastuzumab.
Phase:
Phase 2
Details
Lead Sponsor:
Academic and Community Cancer Research United Seagen Inc.
Collaborators:
Academic and Community Cancer Research United Cascadian Therapeutics Inc. National Cancer Institute (NCI)